The nucleoside analog 2'-nor-2'-deoxyguanosine (2'NDG) effectively inhibits the replication of several laboratory and clinical isolates of human cytomegalovirus. These isolates included viruses obtained from congenitally infected infants and patients suffering from acquired immune deficiency syndrome. The dose of 2'NDG that inhibited cytomegalovirus plaque formation ranged from 0.1 to 1.6 ,ug/ml. At 10 ,ug/ml, 2'NDG completely blocked the production of virus progeny but not the expression of immediate early and early virus gene functions. Cytomegalovirus DNA was not detectable in 2'NDG-treated virus-infected human embryo lung cells when assayed by CsCl density gradient centrifugation. In contrast, the guanosine analog acyclovir at 100 ,ug/ml did not inhibit the production of virus or the synthesis of cytomegalovirus DNA. In virus-infected cells, 2'NDG and acyclovir at 10 and 100 ,ug/ml, respectively, inhibited the incorporation of [3H] Recently, a nucleoside analog of guanosine, 2'-nor-2'-deoxyguanosine (2'NDG), was reported to effectively inhibit herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) replication in a manner apparently similar to acyclovir (ACV) (1, 4, 8, 12) . 2'NDG was thought to be ineffective in preventing human cytomegalovirus (CMV) replication (13). Like ACV, 2'NDG is efficiently phosphorylated by the HSV-1 virus thymidine kinase (TK) but is not a substrate for the cellular enzyme (1, 6). The monophosphate of 2'NDG is rapidly converted to the triphosphate by cellular kinases and then acts as a selective inhibitor of the HSV-1 DNA polymerase (6). Unlike HSV-1 and HSV-2, human CMV lacks a virus-specific TK (5, 20). Instead, human CMV induces elevated levels of the TK of the host cell (5). This fact circumvents the usefulness of antiviral nucleoside analogs, such as ACV, which rely on a virus-specific TK for activation (12). Our studies show that 2'NDG is a potent and effective inhibitor of human CMV replication. The results of these experiments contradict the findings reported by Smith et al. (13) and support the studies of Cheng et al. (2). The experiments described in this manuscript indicate that 2'NDG blocks CMV replication by preventing virus DNA synthesis. These experiments also provide evidence which supports previous studies (2, 6) suggesting a second mechanism of activation for 2'NDG that does not involve a virusspecific TK.
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MATERIALS AND METHODS
Cells and viruses. Human embryonic lung (HEL) and MRC-5 cells were cultured in Dulbecco modified Eagle medium as mentioned previously (18) . Viable cells, determined by trypan blue exclusion, were counted microscopically with a hemacytometer (11) . Methods for the propaga-* Corresponding author. 247 tion of human CMV strains, as well as for HSV types 1 and 2, have been described elsewhere (16, 18) . Virus infectivity was quantitated by plaque assay (19) . Plaque reduction assays were performed in 60-mm plastic tissue culture dishes with ca. 100 PFU of virus per dish. Plates were incubated at least 7 days after infection before the plaques were counted.
Analysis of virus and cell DNA. The procedure for analyzing DNA was that described by Crouch and Rapp (3) . Briefly, cells infected at a virus-to-cell ratio of 1 PFU per cell were pulse-labeled at various times after infection for 12 h in medium containing 10 (3, 16, 18) for CMV and cell DNA (16) .
Chemicals. ACV and 2'NDG were provided by Richard L. Tolman, Merck Sharp & Dohme Research Laboratories, Rahway, N.J. (1) . Compounds were dissolved in phosphatebuffered saline (pH 11.0) or dimethyl sulfoxide and stored at -20°C. In all experiments, 2'NDG and ACV were added to the culture medium after the 1-h virus adsorption period.
RESULTS
Initial experiments demonstrated that 2'NDG was a potent inhibitor of HSV-1 and HSV-2 replication (1, 2, 6). Subsequent studies suggested that like ACV, 2'NDG was activated specifically by a herpes-specific TK (1, (6) (7) (8) 12) but not by the cellular TK. 2'NDG was also shown to be active against both the Towne and AD169 strains of human CMV (2, 6 (Fig. 1) . These studies showed that 2'NDG is 10-to 100-fold more potent than ACV when tested against a number of laboratory and clinical CMV isolates ( Table 1 ). The clinical isolates tested included viruses obtained from congenitally infected infants with cytomegalic inclusion disease (Eisenhardt and CHMC) and patients suffering from acquired immunodeficiency syndrome (AIDS-O.C. and AIDS-D.L.).
In the following experiments, 2'NDG and ACV were used at 10 and 100 ,ug/ml, respectively. At these concentrations, CMV plaque formation is inhibited by 95% or more. ACV at 10,ug/ml did not effectively inhibit CMV replication (Fig. 1 ).
The addition of 2'NDG (10 ,ug/ml) to CMV-infected cell cultures (multiplicity of infection = 0.1 PFU per cell) after virus adsorption blocked the spread of CMV-specific cytopathic effects (CPE) to adjacent cells but did not block the appearance of CPE in infected cells (Fig. 2) . Cells in the culture which were initially infected by CMV developed typical CMV-induced CPE, indicating that immediate early and, at least, partial early virus gene expression occurred in 2'NDG-treated cells (13, 18 radioimmunoassay, two methods which detect the expression of virus polypeptides. It is quite possible that these investigators were detecting CMV immediate early and early antigens which do not require virus DNA synthesis for their expression in 2'NDG-treated cell (15, 17 
